Syros Pharmaceuticals, Inc (SYRS) Long-Term Debt to Capital Ratio

Syros Pharmaceuticals (SYRS) maintains a high level of authority in gene activity regulation for oncology therapy, utilizing precision DNA analysis. The price action on GURU.Markets reflects a metric of 0.00, while demand for leukemia treatments remains significant. Business prospects rely on patent assets and the expected outcomes of tamibarotene trials within targeted medicine partnerships.

This indicator assesses the company's dependence on long-term liabilities relative to its equity. The ratio of loans with a maturity of more than one year to equity determines financial stability and bankruptcy risk. Analyzing the level of long-term debt to equity allows investors to filter out market noise and identify the debt management strategy. For Syros Pharmaceuticals (SYRS), a low debt load is critical, as it ensures financial viability until the completion of Phase 3 clinical trials for tamibarotene and the receipt of FDA approval.